Literature DB >> 1638332

Estimation of premorbid intelligence in schizophrenia.

J R Crawford1, J A Besson, M Bremner, K P Ebmeier, R H Cochrane, K Kirkwood.   

Abstract

To determine whether the National Adult Reading Test (NART) would provide a valid estimate of premorbid intelligence in schizophrenia, two schizophrenic samples were recruited, one consisting of 35 patients resident in long-stay wards, the other of 29 patients normally resident in the community. Schizophrenic patients were individually matched for age, sex, and education with a healthy, normal subject. Both schizophrenic samples scored significantly lower on the Wechsler Adult Intelligence Scale (WAIS) than their respective control groups. NART-estimated IQ did not differ significantly between the community-resident schizophrenics and their controls, suggesting that the NART provides a valid means of estimating premorbid intelligence in such a population. NART-estimated IQ was significantly lower in the long-stay sample than in their controls. Although low NART scores in this latter sample could be a valid reflection of low premorbid IQ, the alternative explanation that NART performance was impaired by onset of the disease cannot be ruled out.

Entities:  

Mesh:

Year:  1992        PMID: 1638332     DOI: 10.1192/bjp.161.1.69

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  12 in total

1.  Premorbid IQ varies across different definitions of schizophrenia.

Authors:  Annick Urfer Parnas; Lennart Jansson; Peter Handest; Jan Nielsen; Ditte Sæbye; Josef Parnas
Journal:  World Psychiatry       Date:  2007-02       Impact factor: 49.548

2.  Forgetting rates in neuropsychiatric disorders.

Authors:  P Lewis; M D Kopelman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-12       Impact factor: 10.154

3.  Cognitive decline in schizophrenic patients: relationship to other symptoms.

Authors:  J T Dalby; R Williams; R Dickson; O Yuen
Journal:  J Psychiatry Neurosci       Date:  1994-11       Impact factor: 6.186

4.  Response selection in schizophrenia.

Authors:  Giuseppe Pellizzer; Massoud Stephane
Journal:  Exp Brain Res       Date:  2007-02-20       Impact factor: 1.972

5.  Intrinsic motivation inventory: an adapted measure for schizophrenia research.

Authors:  Jimmy Choi; Tamiko Mogami; Alice Medalia
Journal:  Schizophr Bull       Date:  2009-04-21       Impact factor: 9.306

6.  Changes in the frontotemporal cortex and cognitive correlates in first-episode psychosis.

Authors:  Leticia Gutiérrez-Galve; Claudia A M Wheeler-Kingshott; Daniel R Altmann; Gary Price; Elvina M Chu; Verity C Leeson; Antonio Lobo; Gareth J Barker; Thomas R E Barnes; Eileen M Joyce; María A Ron
Journal:  Biol Psychiatry       Date:  2010-05-10       Impact factor: 13.382

7.  Sensory integration deficits support a dimensional view of psychosis and are not limited to schizophrenia.

Authors:  O Carter; D Bennett; T Nash; S Arnold; L Brown; R Y Cai; Z Allan; A Dluzniak; K McAnally; D Burr; S Sundram
Journal:  Transl Psychiatry       Date:  2017-05-09       Impact factor: 6.222

8.  Selective impairment of global motion integration, but not global form detection, in schizophrenia and bipolar affective disorder.

Authors:  Daniel Bennett; Amy Dluzniak; Simon J Cropper; Timea Partos; Suresh Sundram; Olivia Carter
Journal:  Schizophr Res Cogn       Date:  2015-12-07

9.  IQ trajectory, cognitive reserve, and clinical outcome following a first episode of psychosis: a 3-year longitudinal study.

Authors:  Verity C Leeson; Pranev Sharma; Masuma Harrison; Maria A Ron; Thomas R E Barnes; Eileen M Joyce
Journal:  Schizophr Bull       Date:  2009-11-24       Impact factor: 9.306

10.  Association of the Hermansky-Pudlak syndrome type 4 (HPS4) gene variants with cognitive function in patients with schizophrenia and healthy subjects.

Authors:  Go Kuratomi; Atsushi Saito; Yuji Ozeki; Takashi Watanabe; Kumiko Fujii; Kazutaka Shimoda; Toshihiko Inukai; Harunobu Mori; Kenichi Ohmori; Kazufumi Akiyama
Journal:  BMC Psychiatry       Date:  2013-10-30       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.